We use Google Analytics to see which pages are read and how the site is used, so we know what to improve. This only runs if you accept. See our privacy notice for details.

Dáil

Written answer

Medicinal Products

1799. Deputy Ivana Bacik asked the Minister for Health if she has made representations to the HPRA in respect of the need to make available 2mg and 1mg doses of a mediction (details supplied) for treating anaphylaxis, approved in August 2025 and March 2026, respectively. [75829/26]

Comment on this

The Health Product Regulatory Authority (HPRA) is the competent authority for the regulation of medicines in Ireland. Medicines placed on the Irish market must be authorised by the HPRA or, in the case of centrally authorised products, by the European Commission.

Epinephrine (Eurneffy®) is an authorised medicinal product in Ireland. The Marketing Authorisation Holder (MAH) has confirmed to the HPRA that Epinephrine (Eurneffy®) 2mg nasal spray solution is currently available for supply to Irish patients, and no shortages are anticipated or ongoing. The MAH has also confirmed to the HPRA that Epinephrine (Eurneffy®) 1mg nasal spray solution is to be made available for supply to Irish patients from November 2026 onwards. As of 21st October 2026, only the 2mg presentation (pack sizes available have not been specified) has been marketed.

The HPRA cannot require companies to market medicinal products in Ireland, and they also have no role in relation to pricing and reimbursement. The HPRA remains willing at any stage to engage with and to provide regulatory guidance to any company who wishes to make medicinal products available in Ireland.

In the event that patients are unable to source a specific medicinal product, they are advised to discuss possible alternatives with their healthcare professional.

Comment on this